Back to results
US 2023/0218684 A1Published application
Engineered bacteria for use in vaccine compositions
AssigneesNorth Carolina State University, Colorado State University Research Foundation
InventorsRodolphe Barrangou, Gregg A. Dean
Life of this patent
Estimating the term…
Abstract
The present disclosure provides materials and methods related to engineered bacteria for use in vaccines. In particular, the present disclosure provides novel compositions and methods for generating vaccine compositions comprising bacteria (e.g., Lactobacillus) engineered to express immunogenic polypeptides and immunogenicity-enhancing adjuvant polypeptides to treat and/or prevent infection from a pathogenic organism (e.g., coronavirus).
Claims34
An engineered bacterial cell comprising:
- (i) an exogenous polypeptide;
- and
- (ii) at least one adjuvant polypeptide;
- wherein the exogenous immunogenic polypeptide and the at least one adjuvant polypeptide are expressed by the bacterial cell.
1 more element
Dependencies are inferred from the claim text.